Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

GHRP-6: does it work, is it legal, and what does it cost?

Original growth hormone releasing peptide; randomized trials measured hormones, sleep, and a combination stroke therapy, not what it is sold for; WADA banned.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about GHRP-6
Does it work in people?Evidence: Human RCT evidence

At least one randomized human trial in PubMed. See the evidence

Is it legal?Regulatory: Not eligible for compounding

Not FDA approved and not on FDA's list of substances pharmacies may compound (the 503A bulks list), so a pharmacy has no federal basis to compound it. [6] [7] See legal status

What does it cost?Not available through licensed US channels.
Side effects?Marked increase in hunger (the most consistently reported effect). Rise in cortisol, ACTH, and prolactin with each dose. Reduced insulin sensitivity and higher blood glucose (cited in FDA's Category 2 rationale). See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is GHRP-6?

GHRP-6 is a synthetic six amino acid peptide first described in 1984 that releases growth hormone by activating the ghrelin receptor (the receptor for the body's hunger hormone), years before ghrelin itself was discovered. Small human studies, some indexed in PubMed as randomized controlled trials, show it releases GH and raises the stress hormones ACTH and cortisol, and it stimulated appetite in rodents, but no randomized trial has tested it for muscle growth, fat loss, or the other uses it is sold for, and it has never been approved anywhere. FDA placed it in 503B Category 2 (ingredients flagged for significant safety risks in outsourcing facility compounding) in September 2023, it has no 503A listing (the pathway for pharmacies compounding for individual patients), and it is prohibited by WADA.

GHRP-6 is a synthetic hexapeptide growth hormone secretagogue (ghrelin receptor agonist), the first of the GHRP series. It is also known as Growth hormone releasing peptide-6, GHRP 6, SKF-110679, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2.

How does it work?

GHRP-6 binds and activates the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs and in the hypothalamus, producing a GH pulse that is synergistic with GHRH. As a ghrelin mimetic it also drives hunger, and it stimulates ACTH, cortisol, and prolactin release. It is the reference compound from which GHRP-2, hexarelin, and ipamorelin were derived.

Key facts
ClusterMetabolic and growth hormone axis
RoutesIntravenous bolus (research studies); Oral (one pediatric study); Subcutaneous injection (as sold, not from published trials)
Conditions studiedGrowth hormone deficiency and GH secretagogue use
Recordv3, reviewed, verified Sep 30, 2026

What does the evidence say about GHRP-6?

Evidence: Human RCT evidenceGrade assigned per the methodology.

A placebo controlled study indexed in PubMed as a randomized controlled trial gave healthy men repeated overnight intravenous injections of GHRP-6 and found higher growth hormone, ACTH, and cortisol and more stage 2 sleep. A 2026 multicenter, open-label, randomized phase III trial in acute ischemic stroke (95 treated patients versus 93 on standard care) gave GHRP-6 only in combination with epidermal growth factor and missed its primary disability endpoint. Other indexed studies gave single doses to healthy volunteers, children, and patients with Cushing's disease, type 1 diabetes, and thyroid disease and measured hormone responses. No randomized trial has tested GHRP-6 for muscle growth, fat loss, or any other use it is sold for.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials4224
Human observational studies320
Animal studies1n/a
All indexed studies8244

Human evidence

Frieboes 1995 gave healthy men 4 intravenous boluses of 50 ug GHRP-6 overnight in a placebo controlled design (indexed in PubMed as a randomized controlled trial; the abstract does not itself say randomized) and found increased GH, ACTH, and cortisol secretion and more stage 2 sleep. Bellone 1995 showed an oral dose (300 ug/kg) released GH in children with short stature, though less than intravenous administration. Camanni 1998 reviews the human pharmacology and notes the consistent rise in cortisol and prolactin. Single dose studies have also compared GHRP-6 with ghrelin and GHRH in 10 patients with Cushing's disease (Correa-Silva 2006), 10 patients with hyperthyroidism (Nascif 2007), and 9 patients with type 1 diabetes (de Sa 2010), measuring hormone responses. Hernandez-Bernal 2026 was a multicenter, open-label, randomized phase III trial in acute ischemic stroke: 95 patients received intravenous GHRP-6 combined with epidermal growth factor twice daily for 7 days and 93 received standard care; it missed its primary disability endpoint, and GHRP-6 was never given alone. No randomized trial has tested GHRP-6 alone for a clinical outcome, and none has tested chronic administration.

Animal evidence

Bowers 1984 described GHRP-6 as a synthetic hexapeptide that specifically released GH from rat pituitary cells in vitro and in vivo, with activity across species. Rodent studies established synergy with GHRH and appetite stimulation. Some rodent work suggests cardioprotective effects shared with hexarelin, but these have not been tested in humans.

Key studies

Indexed studies of GHRP-6
StudyDesign and populationOutcomeGrade
On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone1984 PMID 6714155In vitro pituitary cell and in vivo rat pharmacologyRat pituitary cells and live ratsGHRP-6 specifically released GH in vitro and in vivo, defining the GHRP classEvidence: Animal-only evidence
Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man1995 PMID 7617137Placebo controlled sleep laboratory study; indexed in PubMed as a randomized controlled trial (the abstract does not itself say randomized)Healthy young menFour overnight 50 ug intravenous boluses increased GH, ACTH, and cortisol secretion and stage 2 sleepEvidence: Human RCT evidence
Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature1995 PMID 7581965Pharmacology studyChildren with short statureOral GHRP-6 at 300 ug/kg released GH, with a smaller response than intravenous dosingEvidence: Human observational evidence
Growth hormone-releasing peptides and their analogs1998 PMID 9465289Narrative reviewHuman and animal pharmacology of GHRP-6, GHRP-2, hexarelin, and analogsSummarizes GH releasing potency, synergy with GHRH, and effects on cortisol and prolactinEvidence: Human observational evidence
Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke2026 PMID 42462342Multicenter, open-label, randomized phase III trial of epidermal growth factor plus GHRP-6 versus standard care, twice daily for 7 daysn = 188 Adults with acute ischemic stroke enrolled within 12 hours of symptom onset (95 combination therapy, 93 standard care)Missed its primary endpoint: no difference in disability (modified Rankin Scale), Barthel Index, or survival in the intention to treat population. GHRP-6 was given only in combination, so its own effect cannot be separatedEvidence: Human RCT evidence
Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH2006 PMID 16832586Controlled comparison of single doses of ghrelin, GHRP-6, and GHRH given separatelyn = 20 10 patients with Cushing's disease and 10 controlsGH release after GHRP-6 was blunted in Cushing's disease while ACTH and cortisol responses were enhanced compared with controlsEvidence: Human observational evidence
Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH2007 PMID 17410412Single intravenous doses of ghrelin, GHRP-6, and GHRH; indexed in PubMed as a randomized controlled trial (the abstract does not itself say randomized)n = 18 10 patients with hyperthyroidism and 8 controlsGH release after GHRP-6 was lower in hyperthyroid patients than in controls; GHRP-6 did not raise glucose in either groupEvidence: Human RCT evidence
Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus2010 PMID 20189610Single doses of ghrelin, GHRP-6, and GHRH; indexed in PubMed as a randomized controlled trial (the abstract does not itself say randomized)n = 18 9 patients with type 1 diabetes and 9 controlsGH, ACTH, and cortisol responses to GHRP-6 were similar in patients with type 1 diabetes and controlsEvidence: Human RCT evidence

Conditions studied

Conditions with evidence for GHRP-6
ConditionGradeNote
Growth hormone deficiency and GH secretagogue useNot gradedTesamorelin is FDA approved to reduce abdominal fat in HIV associated lipodystrophy, and sermorelin was previously approved for pediatric GH deficiency. Ipamorelin, CJC-1295, GHRP-2, GHRP-6, hexarelin, and MK-677 raise growth hormone in small human studies but are not approved for any indication and are WADA prohibited.

Is GHRP-6 legal in the United States?

Regulatory: Not eligible for compoundingWADA: WADA prohibited

FDA and compounding status

Not FDA approved for any use. For 503A pharmacies, FDA lists GHRP-6 in Category 3, meaning it was nominated without enough support for FDA to evaluate it. It gets no protection under FDA's interim policy and is not on the 503A bulks list. For 503B outsourcing facilities, FDA placed GHRP-6 in Category 2 on September 29, 2023, citing immunogenicity risk from aggregation and impurities, effects on cortisol, and increased blood glucose from reduced insulin sensitivity. As of the last verification date no licensed pharmacy or outsourcing facility has a lawful basis to compound it.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

  1. WADA

    WADA publishes the 2027 Prohibited List

    WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.

  2. WADA

    WADA 2026 Prohibited List takes effect

    The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.

  3. WADA

    WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times

    The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.

  4. FDA

    FDA places GHRP-2, GHRP-6, and ipamorelin in 503B Category 2

    On September 29, 2023 FDA added growth hormone releasing peptide-2 (GHRP-2, for injectable and nasal routes), GHRP-6, and ipamorelin acetate to Category 2 under the 503B interim policy, citing immunogenicity risk from aggregation and peptide related impurities and, for GHRP-2, reports of serious adverse events. Outsourcing facilities may not compound a substance while it is in 503B Category 2. All three remain listed on the FDA page current as of April 22, 2026.

Full tracker for GHRP-6 or the category-wide tracker.

Email me when GHRP-6's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of GHRP-6 used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Acute study doses only: 1 ug/kg intravenous bolus in adults, 4 x 50 ug intravenous overnight in the sleep study (Frieboes 1995), and 300 ug/kg orally in children (Bellone 1995). No chronic therapeutic dose has been established in human literature; subcutaneous regimens sold online are not from any published trial.

Routes reported

Routes of administration reported for GHRP-6
#Route
1Intravenous bolus (research studies)
2Oral (one pediatric study)
3Subcutaneous injection (as sold, not from published trials)

What are the side effects and interactions of GHRP-6?

Side effects

Side effects reported for GHRP-6
#Reported side effect
1Marked increase in hunger (the most consistently reported effect)
2Rise in cortisol, ACTH, and prolactin with each dose
3Reduced insulin sensitivity and higher blood glucose (cited in FDA's Category 2 rationale)
4Flushing, warmth, and sweating after intravenous doses
5Water retention and tingling reported with GH secretagogues generally
6No long term human safety data

Interactions

Interactions reported for GHRP-6
#Interaction
1Insulin and oral diabetes medications: GH secretagogues raise blood glucose
2Glucocorticoids: additive cortisol exposure because GHRP-6 raises ACTH
3GHRH analogs (sermorelin, CJC-1295): synergistic GH release, untested long term
4No formal human drug interaction studies exist

Contraindications

Contraindications for GHRP-6
#Contraindication
1Active cancer (theoretical GH and IGF-1 driven tumor growth)
2Diabetes or impaired glucose tolerance without monitoring
3Pregnancy and breastfeeding (no data)
4Athletes subject to WADA testing (prohibited at all times under S2)

How do people access GHRP-6 legally?

Typical cost: Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Access options

  • Not available

    No lawful United States access path identified on the last verified date: it is not FDA approved and is not on the 503A bulks list.

  • Not available

    Not available as an FDA approved product; FDA placed GHRP-6 in 503B Category 2 on September 29, 2023 and it has no 503A nomination or listing.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare GHRP-6

What's actually offered, and what that means for you

FDA has found compounding pharmacies offering GHRP-6 anyway. [10] [11]

Being offered does not change the legal status of GHRP-6. GHRP-6 is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [6] [7]

What FDA found

  • April 2020: FDA named GHRP-6 among the bulk substances a state-licensed 503A pharmacy compounded outside section 503A. [11]
  • February 2019: FDA told a 503A pharmacy that drugs it compounded from GHRP-2 and GHRP-6 were not eligible for section 503A exemptions. [10]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [6] [12] [13] [14] [15] [16]

What that means for you

  • A pharmacy that compounds GHRP-6 is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [12] [13]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [16]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [17]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [18] [19]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [6]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, GHRP-6 is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [8]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound GHRP-6, with or without a prescription. [7]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [20] [21] [22]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [22] [23] [24]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [16] [25] [26] [27] [28] [29]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [16]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [20]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [24]
  • Pharmacy: Is this made for me on a prescription written in my name? [23]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [22] [24]
  • Prescriber: What is the legal basis for a pharmacy to compound GHRP-6? Is it FDA approved or on the 503A bulks list? [7] [16]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [24]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [17]

Frequently asked questions

Is GHRP-6 legal in the United States?

It is not FDA approved and has no federal basis to be compounded (custom-made by a pharmacy). FDA placed GHRP-6 in 503B Category 2 (substances with significant safety risks) on September 29, 2023, and it has never been nominated for the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), so no licensed pharmacy can compound it. Possession is not a crime, but selling it for human use is unlawful: research chemical products are unapproved drugs and are untested for purity. [6] [7] [9]

Does GHRP-6 work for muscle growth or fat loss?

It has not been tested for either. The randomized evidence is an overnight placebo controlled study in healthy men that measured hormones and sleep, and a stroke trial that gave GHRP-6 only in combination with another drug. Other published studies measured hormone levels after single doses: GHRP-6 releases GH, and it does so orally as well as intravenously. No trial has measured muscle, fat, or strength with repeated dosing. Because it also raises cortisol, and stimulated appetite in rodents, a net body composition benefit cannot be assumed from GH physiology alone. [2] [3] [4] [5]

What are the side effects of GHRP-6?

Hunger is the effect users most often describe. GHRP-6 acts on the ghrelin (hunger hormone) receptor and stimulated appetite in rodents, but none of the published human studies cited here measured appetite. Controlled dosing studies show rises in cortisol, ACTH, and prolactin alongside GH. FDA's Category 2 rationale cites reduced insulin sensitivity and increased blood glucose. There are no long term safety data in humans. [2] [6]

How is GHRP-6 taken?

In published studies it was given as intravenous boluses (for example 50 ug repeated overnight, or 1 ug/kg) and orally at 300 ug/kg in children. Products sold online are subcutaneous injection vials taken one to three times daily, a schedule that has never been studied in a published trial. [2] [3]

How much does GHRP-6 cost?

There is no licensed US price because no pharmacy can lawfully compound it. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [6] [9]

Is GHRP-6 banned by WADA?

Yes. Growth hormone secretagogues and growth hormone releasing peptides, including GHRP-6, are prohibited at all times under section S2 of the WADA Prohibited List. [8]

GHRP-6 vs ipamorelin: which is better?

Ipamorelin was designed from the GHRP series to release GH with less effect on cortisol, ACTH, and prolactin, and it causes less hunger, so it is usually described as the more selective compound. GHRP-6 releases GH robustly but also raises cortisol. Neither has long term human outcome data, both were placed in FDA 503B Category 2 in September 2023, and both are WADA prohibited. [4] [6]

Does GHRP-6 work orally?

Partly. A 1995 study in children with short stature found that 300 ug/kg of GHRP-6 given orally released GH, though the response was smaller than with intravenous dosing. Oral bioavailability is low, which is why later development focused on non peptide oral secretagogues such as MK-677. [1] [3]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984PubMed 6714155, 1984
  2. [2]Frieboes RM et al. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 1995PubMed 7617137, 1995
  3. [3]Bellone J et al. Growth hormone-releasing effect of oral GHRP-6 administration in children with short stature. Eur J Endocrinol 1995PubMed 7581965, 1995
  4. [4]Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol 1998PubMed 9465289, 1998
  5. [5]Hernandez-Bernal F et al. Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke. J Clin Neurosci 2026PubMed 42462342, 2026
  6. [6]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  7. [7]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  8. [8]WADA Prohibited List, section S2 peptide hormones, growth factors, related substances and mimeticsWADA, 2026
  9. [9]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  10. [10]FDA warning letter 553916, February 11, 2019, to a 503A compounding pharmacy (FDA warning letters database)FDA, 2019

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 30). GHRP-6: evidence, legality, and access. https://peptideagent.ai/peptides/ghrp-6
HTML link
<a href="https://peptideagent.ai/peptides/ghrp-6">GHRP-6: evidence, legality, and access</a>, PeptideAgent, updated September 30, 2026.